ANGPTL3
ENSG00000132855
Target class
Unclassified protein
Chromosome
1
Approved drugs
1
Clinical candidates (approved and in development)
1
- Approved drugs
- 1
- ClinGen gene-disease validity
- Definitive
- Clinical candidates (approved and in development)
- 1
- Chemical probe available
- No
- Target name
- ANGPTL3
- Gene name
- Angiopoietin like 3
- Gene symbol
- ANGPTL3
- Previous gene symbols
- ANGPT5
- Protein name
- Angiopoietin-related protein 3 (Angiopoietin-5) (ANG-5) (Angiopoietin-like protein 3) [Cleaved into: ANGPTL3(17-221); ANGPTL3(17-224)]
- Gene biotype
- Protein coding
- Gene family
- Receptor ligands|Fibrinogen C domain containing|Angiopoietin like family
- Target class
- Unclassified protein
- Target type
- Human gene
- Tissues expressed in
- 4
- Highest tissue expression
- 133.78
- Tissue specificity (Gini)
- 0.954
- Tissue specificity (tau)
- 0.998
- KEGG gene identifiers
- hsa:27329
- Protein interaction confidence
- 0.839167
- Protein interaction partners
- 12
- R-HSA-8963889
- R-HSA-9029558
- End position
- 62607196
- Start position
- 62597464
- Chromosome
- 1
- Strand
- Forward
- Secreted . Cell projection, lamellipodium . Note=Colocalized with HSPG2 and activated ITGB3 on podocytes. .
Publication evidence
- PubMed 11877390
- Tissue specificity (tau)
- 0.997944
- Expression inequality (Gini)
- 0.953569
Expression in transcripts per million
- Liver
- 133.78
- Kidney - Cortex
- 5.13
- Kidney - Medulla
- 1.96
- Stomach
- 1.65
- Pituitary
- 0.45
Expression in transcripts per million
- Liver133.78
- Kidney - Cortex5.13
- Kidney - Medulla1.96
- Stomach1.65
- Pituitary0.45
- Ovary0.41
- Cervix - Ectocervix0.29
- Artery - Aorta0.28
- Testis0.28
- Uterus0.25
- Vagina0.25
- Cervix - Endocervix0.25
- Minor Salivary Gland0.22
- Nerve - Tibial0.19
- Artery - Tibial0.19
- Thyroid0.17
- Skin - Not Sun Exposed (Suprapubic)0.17
- Fallopian Tube0.16
- Prostate0.16
- Artery - Coronary0.16
- Bladder0.15
- Pancreas0.15
- Brain - Cerebellum0.11
- Lung0.11
- Skin - Sun Exposed (Lower leg)0.11
And 29 more, listed on the interactive page.
- GO:0006071
- GO:0006631
- GO:0006644
- GO:0007160
- GO:0007165
- GO:0008203
- GO:0009395
- GO:0010903
- GO:0019915
- GO:0030335
- GO:0042632
- GO:0045766
- GO:0050996
- GO:0055088
- GO:0055090
- GO:0055091
- GO:0070328
- GO:0090318
- GO:1905883
- GO:0005576
- GO:0009986
- GO:0004859
- GO:0005178
- GO:0008083
- GO:0035473
- GO:0055102
Related records
Trials (20)
- A Dose-Ranging Study With Vupanorsen (TRANSLATE-TIMI 70)
- A Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Tolerability Of Single Dose Vupanorsen In Healthy Chinese Adults
- Compassionate Use of Evinacumab
- Efficacy and Safety of Evinacumab in Adult Patients With Severe Hypertriglyceridemia for the Prevention of Recurrent Acute Pancreatitis
- Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia
- Evaluate the Efficacy and Safety of Evinacumab in Pediatric Patients With Homozygous Familial Hypercholesterolemia
- Evaluate the Long-Term Safety and Efficacy of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia
- Investigation Of Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Single Doses Of Vupanorsen In Japanese Healthy Adult Participants With Elevated Triglycerides
- Phase 2 Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants With Familial Chylomicronemia Syndrome (FCS)
- Safety and Effectiveness of Evinacumab for the Treatment of Homozygous Familial Hypercholesterolemia
- Safety and Efficacy Following Repeat-Dose of Evinacumab (Anti-ANGPTL3) in Patients With Severe Hypertriglyceridemia (sHTG) at Risk for Acute Pancreatitis
- Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants With Familial Partial Lipodystrophy (FPL)
- Study of AKCEA-ANGPTL3-LRX (ISIS 703802) in Patients With Homozygous Familial Hypercholesterolemia (HoFH)
- Study of Evinacumab (REGN1500) in Caucasian and in Japanese Healthy Volunteers
- Study of Evinacumab (REGN1500) in Participants With Persistent Hypercholesterolemia
- Study of ISIS 703802 in Participants With Hypertriglyceridemia, Type 2 Diabetes Mellitus, and Nonalcoholic Fatty Liver Disease
- Study of REGN1500 in Participants With Homozygous Familial Hypercholesterolemia (HoFH)
- Study to Assess the Effects of Angiopoietin-like Protein 3 (ANGPTL3) Inhibition in Adult Participants With Diabetic Kidney Disease
- Study to Assess the Safety and Tolerability of Multiple Ascending Doses of REGN1500
- Study to Assess the Safety and Tolerability of Single Doses of REGN1500
Drugs (3)
- Evinacumab Angiopoietin-related protein 3 inhibitor
- Vupanorsen Angiopoietin like 3 (ANGPTL3) mRNA antisense inhibitor
- Vupanorsen sodium Angiopoietin like 3 (ANGPTL3) mRNA antisense inhibitor